home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2797.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
2KB
|
34 lines
Document 2797
DOCN M94A2797
TI Response to N-acetyl-L-cysteine on the CD4-CD8 system.
DT 9412
AU Focaccia R; Cattapan A; Conceicao O; Buainain R; Salaroli A; Focaccia
MT; Fac. Medicina Jundiai, Brazil.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):222 (abstract no. PB0319). Unique
Identifier : AIDSLINE ICA10/94369778
AB We report the first results of a clinical trial conducted to test the
response of CD4-CD8 lymphocyte system to the administration of
N-Acetyl-L-Cysteine (NAC). HIV-positive patients bearing CD4 counts <
500 cells/mm3 measured by flow cytometry were studied. Patients were
divided in 2 groups that received doses every 12 Hs during 1 mo., 8
cases Parenteral, 400 mg. 7 cases Oral, 600 mg. Five of the patients
were being treated with AZT without significant change of CD4 counts.
RESULTS: TABULAR DATA, SEE ABSTRACT VOLUME. Two of the 8 successful
cases became serum p24 antigen negative. The 6 cases of the parenteral
group ceased to develop opportunistic infections so far. No side effects
were reported in both groups. CONCLUSION: NAC associated to antiviral
therapy can be a powerful immunotherapy drug. Current research effort is
aimed to determine the clinical meaning of CD4-CD8 enhancement and the
determination of a suitable maintenance schedule.
DE Acetylcysteine/ADMINISTRATION & DOSAGE/*PHARMACOLOGY/THERAPEUTIC USE
Adjuvants, Immunologic/ADMINISTRATION & DOSAGE/*PHARMACOLOGY/
THERAPEUTIC USE Administration, Oral Flow Cytometry Human HIV
Infections/IMMUNOLOGY/*THERAPY Injections Leukocyte Count/*DRUG
EFFECTS T-Lymphocytes, Cytotoxic/*DRUG EFFECTS Treatment Outcome T4
Lymphocytes/*DRUG EFFECTS Zidovudine/THERAPEUTIC USE CLINICAL TRIAL
MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).